FINLIUS (ustekinumab) is not covered on the Reformulary. Reformulary covers three preferred ustekinumab biosimilars that offer the same clinical value at a lower net cost to the plan. The biosimilars, WEZLANA, STEQEYMA and OTULFI require Special Authorization.

Biosimilars are safe and clinically similar to the originator biologic, and have the potential to provide significant savings to you and your plan – this is essential to drug plan sustainability.
 

Jamteki is used to treat  
Psoriasis
Psoriatic Arthritis